Answer
Gastrointestinal reactions were the most frequently reported adverse reactions during treatment in adult weight-management trials of Saxenda (liraglutide), occurring in 67.9%.
Sources for this answer
- Saxenda 6 mg/mL solution for injection in pre-filled penNovo Nordisk Limited · emc · SmPC §4.8 Undesirable effects · Version 16Document updated
Sources checked